VICTORIA, July 10, 2017 /CNW/ - Emerald Health
Therapeutics Inc. (TSXV:EMH) ("Emerald" or the "Company") announced
today that its trading symbol on the OTCQX has been changed to
EMHTF.
The OTCQX® Best Market is the top tier of financial markets in
the OCT Marketplace system. To qualify for OTCQX, companies must
meet high financial standards, follow best practice corporate
governance, demonstrate compliance with U.S. securities laws, and
have a professional third-party sponsor introduction. The companies
found on OTCQX are distinguished by the integrity of their
operations and diligence with which they convey their
qualifications.
Join us on our journey of making lives better through
cannabis science.
Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF)
operates primarily through Emerald Health Botanicals Inc.
("Botanicals"), a wholly owned subsidiary of the Company and a
Licensed Producer under the Access to Cannabis for Medical Purposes
Regulations (ACMPR). Botanicals is authorized to produce and sell
both dried medical cannabis flowers and medical cannabis oils in
Canada. Botanicals currently
operates an indoor facility in Victoria,
British Columbia, with plans for expansion on a 32-acre
property in Metro Vancouver and a joint venture with Village Farms
utilizing 25 acres of greenhouse complex in Delta, BC. Botanicals is one of Canada's most medically focused licensed
producers, with a team of highly qualified management experienced
in pharmaceutical drug discovery, development and distribution.
Emerald's vision is to be a leading provider of cannabis products
through its production capabilities, proprietary genetics and
intellectual property, value-added products and branding, and
superb customer experience.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements.
Forward-looking statements include, but are not limited to,
statements with respect to legalization of non-therapeutic cannabis
sales in Canada; participation in
the legalized non-therapeutic cannabis industry; growth in the
extract-based market; increased production of cannabis; commercial
operations; construction or conversion of production facilities;
applications for licensing; obtaining such licenses; commencement
of production of cannabis at the Company's facilities; estimates of
production capacity at such facilities; contributions of cash to
the JV; international opportunities for the Company; commencement
of clinical trials; the Company becoming a leading Canadian
supplier of cannabis products; expected timing of any of the above
matters; and other information that is based on forecasts of future
results, estimates of amounts not yet determinable and assumptions
of management.
Emerald Health Therapeutics Inc. does not intend, and does
not assume any obligation, to update these forward-looking
statements except as required by law. These forward-looking
statements involve risks and uncertainties relating to, among other
things, failure of the federal government to approve legislation
legalizing sales of non-therapeutic adult-use cannabis; failure to
obtain Health Canada and other regulatory approvals; failure to
obtain necessary financing; results of production and sale
activities; the Company's historical experience with medical
marijuana operations; results of scientific research; uninsured
risks; regulatory changes; difficulties in construction or in
obtaining qualified contractors to complete construction or
conversion of facilities; availability of production facilities;
timeliness of government approvals and the granting of permits and
licenses; changes in prices and costs; actual operating and
financial performance of facilities; equipment and processes
relative to specifications and expectations; as well as the other
risk factors set out in the Company's annual information form and
other filing with the applicable Canadian securities regulators,
which may be viewed at www.sedar.com. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
SOURCE Emerald Health Therapeutics, Inc.